In the ever-evolving world of medicine, innovations are constantly emerging to improve patient care and outcomes. One such breakthrough comes from ViaDerma, a pharmaceutical company that has developed a groundbreaking transdermal delivery technology by transforming oral medications into potent topical ointments for rapid, targeted results.
Founded in 2014 by Dr. Christopher Otiko, ViaDerma is committed to providing advanced solutions to the healthcare industry for wound care treatments and a variety of infectious skin diseases, while targeting several global markets worth over $366 billion and growing.
In this exclusive interview, we delve into the secrets behind ViaDerma’s cutting-edge technology, the unique features of their lead product, Vitastem Ultra, and the company’s plans for expanding its impact on global markets.
Interview with ViaDerma’s CEO, Dr. Christopher Otiko
What industries do you license your transdermal technology to?
We currently offer our proprietary transdermal technology licensing to leaders within the pharmaceutical, wound care, pet care, and cosmetics industries. Our wound care and infectious skin disease solutions are targeted to helping hospitals, surgery centers, nursing homes, wound care facilities, to veterinarians, sports injuries, and more treat and heal infectious skin diseases to surgical & diabetic wounds too.
What makes your product offerings so special?
A few things, but it’s really all about the chemistry. You see, unlike pretty much all known antibiotics that primarily use what’s referred to as a chemical “mechanism of kill” only, whereby the antibiotic attempts to kill the bacteria slowly by applying more and more of the medicine over a period of time as it is taken as prescribed, whether it’s topical or orally administered. Although this method can be somewhat effective, it takes much longer to perform. Unfortunately, this process allows for bacteria to evolve and develop a resistance to the medicine.
This is where our proprietary transdermal technology behind a product like Vitastem Ultra is different, in that is uses both a chemical and a physical mechanism to fight and kill pathogens. The physical mechanism of kill is a key feature of Vitastem’s strength.
What are a few key product differentiators?
There are many, but here are a few of them…
- Vitastem Ultra is the only antibiotic in the world that kills with both a physical and chemical mechanism, giving it a unique ability to defeat drug resistant bacteria.
- Vitastem Ultra kills all known bacteria it has ever been tested against, including common antibiotic-resistant MRSA (flesh-eating bacteria) and Staph Infection.
- Vitastem Ultra has saved countless patients from amputations, while helping to reduce their hospital stays and increase their life expectancy.
- Vitastem Ultra has a unique ability to heal and regenerate tissue unlike any other medication on the market.
- Vitastem Ultra is safe to use for any age group. It’s a Class-1 medical product (in the safest of medical categories) and available for over the counter (OTC). Plus, being a topical antibiotic, it will not harm the kidneys or the good bacteria in the stomach, unlike oral antibiotics.
How did you get started in the medical field?
I got my BS in Biochemistry at Ilorin University in Ilorin, Nigeria. After that, I went on to get my master’s degree in Biochemistry at Oklahoma State University, Stillwater OK. Then, I went on to attend what was then called the California College of Podiatric Medicine in San Francisco, CA where I obtained my Doctor of Podiatric Medicine degree.
Where did you grow up?
I was born in Nigeria, but I left there when I was about 3 years old. I was raised in London, England and lived there until I was 14. I then moved back to Nigeria where I lived for about 8 more years. While deciding to go chase the “American Dream,” I ended up moving to the US when I was 22 to attend graduate school.
How does ViaDerma plan on penetrating your target global markets?
We’re already pretty active in doing so with targeting our solutions to wound care networks nationwide, along with pursuing opportunities with many hospitals, surgical centers, and universities too. We are in the process of ramping up sales staff and recently hired a top marketing agency to help with brand development and growing the business online too.
The Next Steps for ViaDerma
ViaDerma is revolutionizing the treatments for infectious skin diseases and wound care through its innovative transdermal delivery technology system. The company’s lead product, Vitastem Ultra, boasts numerous unique advantages, including its dual chemical and physical mechanisms of action, its ability to kill all known bacteria it has been tested against, and its skin tissue regeneration capabilities.
With a growing commitment to providing advanced solutions to a wide range of industries, including pharmaceuticals, wound care, pet care, and cosmetics, ViaDerma is poised to make a significant impact in several global markets. In addition to these markets, ViaDerma recently announced they will be unveiling a far more advanced hair regrowth formula, Nupelo, which will compete with leading brands on a global scale in 2023. Nupelo will use 5% minoxidil as the active ingredient, along with ViaDerma’s proprietary transdermal delivery system, as they feel this will be the most advanced hair restoration product on the market soon. Not only will it help people reduce their hair falling out, but it will also help regrow their hair too.
The company’s founder, Dr. Christopher Otiko, brings a wealth of experience and passion to the field, with a focus on improving patient outcomes and reducing the risk of complications such as amputations. As ViaDerma continues to grow, it aims to penetrate its target global markets by partnering with wound care networks, hospitals, surgical centers, and universities.
By expanding its sales staff and collaborating with a top marketing agency, ViaDerma is well-positioned to transform the landscape for treating infectious skin diseases and wound care on a global scale.
By offering a powerful, effective, and safe alternative to traditional antibiotics, ViaDerma has the potential to change the way we approach treating skin infections and wounds, especially antibiotic-resistant bacteria like MRSA (flesh-eating bacteria) and staph infection, which are common HAIs (healthcare-acquired infections) that results in millions of needless infections, hundreds of thousands of deaths, and billions of dollars in excess costs to healthcare.
This innovative company is not only pushing the boundaries of current medical technology, but it is also committed to improving the lives of countless patients worldwide. With its unique transdermal technology and dedication to excellence, ViaDerma is quickly becoming an essential player in the future of medicine and health care for billions.